SDC2
Syndecan-2
Also known as: CD362, fibroglycan, HSPG, HSPG1, SDC2_HUMAN, SYND2
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P34741
- Gene
- SDC2
- Ensembl
- ENSG00000169439
- Chromosome
- 8
- Canonical length
- 201 aa
- Protein class
- CD markers, Predicted membrane proteins
- Subcellular location
- Plasma membrane
OverviewNCBI Gene
The protein encoded by this gene is a transmembrane (type I) heparan sulfate proteoglycan and is a member of the syndecan proteoglycan family. The syndecans mediate cell binding, cell signaling, and cytoskeletal organization and syndecan receptors are required for internalization of the HIV-1 tat protein. The syndecan-2 protein functions as an integral membrane protein and participates in cell proliferation, cell migration and cell-matrix interactions via its receptor for extracellular matrix proteins. Altered syndecan-2 expression has been detected in several different tumor types. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
201 residues, UniProt reviewed canonical sequence.
>P34741|SDC2
1 MRRAWILLTL GLVACVSAES RAELTSDKDM YLDNSSIEEA SGVYPIDDDD YASASGSGAD
61 EDVESPELTT SRPLPKILLT SAAPKVETTT LNIQNKIPAQ TKSPEETDKE KVHLSDSERK
121 MDPAEEDTNV YTEKHSDSLF KRTEVLAAVI AGGVIGFLFA IFLILLLVYR MRKKDEGSYD
181 LGERKPSSAA YQKAPTKEFY ALocalizationUniProt · AlphaFold · HPA
Whether an antibody against SDC2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.66
- Highest tissue expression
- 430 nTPM
Expression across tissuesHPA
Tissue
- liver: 430 nTPM
- thyroid gland: 398 nTPM
- ovary: 191 nTPM
- blood vessel: 188 nTPM
- cervix: 147 nTPM
- placenta: 117 nTPM
Single-cell type
- breast lactating cells: 359 nCPM
- hepatocytes: 328 nCPM
- decidual stromal cells: 310 nCPM
- fibro-adipogenic progenitors: 307 nCPM
- gonadotrophs: 295 nCPM
- pituicytes/fscs: 282 nCPM
Immune cell
- neutrophil: 14 nTPM
- classical monocyte: 2 nTPM
- myeloid DC: 1.3 nTPM
- total PBMC: 0.6 nTPM
- intermediate monocyte: 0.2 nTPM
- naive CD4 T-cell: 0.2 nTPM
Brain region
- hypothalamus: 80 nTPM
- thalamus: 73 nTPM
- midbrain: 71 nTPM
- medulla oblongata: 58 nTPM
- basal ganglia: 57 nTPM
- spinal cord: 52 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.67
- gnomAD pLI
- 0.4
- gnomAD missense Z
- 0.46
- DepMap mean gene effect
- 0.01
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of SDC2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SDC2 as an antibody target. Whether an autoantibody or antibody against SDC2 could matter depends on whether native SDC2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SDC2 is annotated at the cell surface, where native SDC2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label SDC2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...